Dr. O'Donnell on Up-front Triplets in Multiple Myeloma

Betsy O'Donnell, MD, discusses the utility of up-front triplet regimens in multiple myeloma.

Betsy O'Donnell, MD, medical oncologist in the Multiple Myeloma Disease Center and director of Lifestyle Medicine at the Massachusetts General Hospital, discusses the utility of up-front triplet regimens in multiple myeloma.

Most elderly patients with multiple myeloma who are transplant ineligible and younger patients who are transplant eligible are treated with a triplet regimen, says O'Donnell. Physicians will typically draw from the proteasome inhibitor class and immunomodulatory drugs with dexamethasone as the standard. The combination of lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone is a classic up-front regimen that is used in this space. Data with carfilzomib (Kyprolis) plus lenalidomide and dexamethasone in multiple myeloma are also available.

Now, the standard of care is being challenged with the addition of monoclonal antibodies, such as daratumumab (Darzalex) in the up-front setting, adds O'Donnell. Some recent phase 3 data were presented over the past year that are very exciting. As of this moment, triplets typically serve as the standard induction regimen in this space, concludes O'Donnell.

Related Videos
Kimberly Cannavale, MPH
Laurence Albigès, MD, PhD
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD